PGE-M

PGE-M is a metabolite of prostaglandin E2 (PEG2) as a biomarker of inflammation and cancer including advanced colorectal neoplasia, ovarian cancer, prostate cancer and so on. Urinary PGE-M is positively associated with obesity, smoking and lung metastases with breast cancer[1][2][3].

Product Specifications

CAS Number

[24769-56-0]

Product Name Alternative

Tetranor-PGEM

UNSPSC

12352211

Hazard Statement

H225, H319, H336

Target

Endogenous Metabolite

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/pge-m.html

Concentration

304.54 μM * 250 μL in Methyl acetate

Purity

99.9

Solubility

10 mM in DMSO

Smiles

O[C@H]1[C@@H]([C@H](C(C1)=O)CCC(O)=O)CCC(CCCCC(O)=O)=O

Molecular Formula

C16H24O7

Molecular Weight

328.36

Precautions

H225, H319, H336

References & Citations

[1]Johnson JC, et al. Urine PGE-M: A metabolite of prostaglandin E2 as a potential biomarker of advanced colorectal neoplasia. Clin Gastroenterol Hepatol. 2006 Nov;4 (11) :1358-65.|[2]Wang D, DuBois RN. Urinary PGE-M: a promising cancer biomarker. Cancer Prev Res (Phila) . 2013 Jun;6 (6) :507-10.|[3]Morris PG, et al. Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging, and lung metastases in patients with breast cancer. Cancer Prev Res (Phila) . 2013 May;6 (5) :428-36.